CA2367903A1 - Novel method for producing doxazosin mesylate in a crystalline modification designated as form a - Google Patents

Novel method for producing doxazosin mesylate in a crystalline modification designated as form a Download PDF

Info

Publication number
CA2367903A1
CA2367903A1 CA002367903A CA2367903A CA2367903A1 CA 2367903 A1 CA2367903 A1 CA 2367903A1 CA 002367903 A CA002367903 A CA 002367903A CA 2367903 A CA2367903 A CA 2367903A CA 2367903 A1 CA2367903 A1 CA 2367903A1
Authority
CA
Canada
Prior art keywords
doxazosin
doxazosin mesylate
mesylate
methanol
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002367903A
Other languages
English (en)
French (fr)
Inventor
Peter Klein
Marco Thyes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2367903A1 publication Critical patent/CA2367903A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002367903A 1999-03-18 2000-03-06 Novel method for producing doxazosin mesylate in a crystalline modification designated as form a Abandoned CA2367903A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19912063A DE19912063A1 (de) 1999-03-18 1999-03-18 Neues Verfahren zur Herstellung von Doxazosin-Mesylat in einer als Form A bezeichneten Kristallmodifikation
DE19912063.3 1999-03-18
PCT/EP2000/001939 WO2000056731A1 (de) 1999-03-18 2000-03-06 Neues verfahren zur herstellung von doxazosin-mesylat in einer als form a bezeichneten kristallmodifikation

Publications (1)

Publication Number Publication Date
CA2367903A1 true CA2367903A1 (en) 2000-09-28

Family

ID=7901411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002367903A Abandoned CA2367903A1 (en) 1999-03-18 2000-03-06 Novel method for producing doxazosin mesylate in a crystalline modification designated as form a

Country Status (13)

Country Link
EP (1) EP1165548A1 (ja)
JP (1) JP2002540109A (ja)
KR (1) KR20010113753A (ja)
CN (1) CN1352643A (ja)
AU (1) AU3960800A (ja)
CA (1) CA2367903A1 (ja)
CZ (1) CZ20013347A3 (ja)
DE (1) DE19912063A1 (ja)
HU (1) HUP0200663A2 (ja)
IL (1) IL144944A0 (ja)
PL (1) PL350088A1 (ja)
TR (1) TR200102730T2 (ja)
WO (1) WO2000056731A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19912573A1 (de) * 1999-03-19 2000-09-21 Knoll Ag Arzneimittel, enthaltend Doxazosin-Mesylat der Kristallmodifikaton D
CA2706372A1 (en) 2007-12-24 2009-07-02 Cipla Limited Crystalline polymorph of doxazosin mesylate (form iv) and process for preparation thereof
CN109988158A (zh) * 2018-01-03 2019-07-09 合肥立方制药股份有限公司 X晶型、含有x晶型的多沙唑嗪甲磺酸盐及其制备方法和用途
CN111303130B (zh) * 2018-12-11 2021-09-14 合肥立方制药股份有限公司 一种多沙唑嗪甲磺酸盐晶型、其制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1287588B1 (it) * 1996-12-13 1998-08-06 Alfa Chem Ital Forma cristallina del doxazosin mesilato e processo per la sua produzione
PT849266E (pt) * 1996-12-20 2007-03-30 Heumann Pcs Gmbh Nova forma polimorfa de mesilato de doxazosina (forma iii)
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür

Also Published As

Publication number Publication date
PL350088A1 (en) 2002-11-04
KR20010113753A (ko) 2001-12-28
EP1165548A1 (de) 2002-01-02
TR200102730T2 (tr) 2002-06-21
CZ20013347A3 (cs) 2002-01-16
JP2002540109A (ja) 2002-11-26
DE19912063A1 (de) 2000-09-21
IL144944A0 (en) 2002-06-30
WO2000056731A1 (de) 2000-09-28
AU3960800A (en) 2000-10-09
CN1352643A (zh) 2002-06-05
HUP0200663A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
RU2291861C2 (ru) Способ получения производных хинолина
CA2058619C (en) Process for the preparation of substituted isoflavone derivatives
EA022813B1 (ru) СПОСОБ ОЧИСТКИ МЕТИЛ{4,6-ДИАМИНО-2-[1-(2-ФТОРБЕНЗИЛ)-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ]ПИРИМИДИН-5-ИЛ}МЕТИЛКАРБАМАТА И ЕГО ПРОИЗВОДНОЕ В ВИДЕ СУЛЬФИНИЛДИМЕТАНА
CZ2003566A3 (cs) Způsob přípravy hydrátů olanzapinu a jejich konverze na krystalické formy olanzapinu
CA2367903A1 (en) Novel method for producing doxazosin mesylate in a crystalline modification designated as form a
US6130218A (en) Polymorphic form of doxazosin mesylate (Form I)
RU2334748C2 (ru) Способ получения 7-этил-10-[4-(1-пиперидино)-1-пиперидино] карбонилоксикамптотецина
US20090012296A1 (en) Processes for the preparation of crystalline form beta of imatinib mesylate
RU2228931C2 (ru) Кристаллические формы 3-(2,4-дихлорбензил)-2-метил-n-(пентилсульфонил)-3h- бензимидазол-5-карбоксамида
US6500830B1 (en) Conversion of modification D to modification A of doxazosin mesylate
KR100659927B1 (ko) 다형태를갖는독사조신메실레이트의새로운형태(제iii형)
AU724705B2 (en) New polymorphous form of doxazosin mesylate (Form II)
JP2002513021A (ja) 1,3−二置換−4−オキソ環式尿素の製造方法
EP1162202B1 (en) Method for obtaining polymorph a from doxazosine mesylate
EA008055B1 (ru) Кристаллические формы оланзапина и способы их получения
JP4514950B2 (ja) 1,3−二置換−4−オキソ環式尿素の製造方法
EP3002286B1 (en) Preparation method for polymorphic 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine and use thereof
JP2014504281A (ja) 酒石酸によるトリアジン誘導体エナンチオマーの分離
RU2335503C2 (ru) Кристаллы сольвата производного хинолинкарбоновой кислоты
AU2163501A (en) Method for producing epinastine hydrochloride in the high-melting crystal modification
TWI857250B (zh) 單水合曲前列環素晶體及其製備方法
EP3992173B1 (en) Treprostinil monohydrate crystals and methods for preparation thereof
EP4083045B1 (en) Novel method for synthesizing decursin derivative
CA2504796A1 (en) Polymorphs of pantoprazole sodium salt and process for the preparation thereof
JPH0739410B2 (ja) 6−(3−ジメチルアミノプロピオニル)フォルスコリンの新規製造法

Legal Events

Date Code Title Description
FZDE Discontinued